Prescient Therapeutics Ltd (AU:PTX) — Market Cap & Net Worth
Market Cap & Net Worth: Prescient Therapeutics Ltd (PTX)
Prescient Therapeutics Ltd (AU:PTX) has a market capitalization of $40.18 Million (AU$56.78 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #22655 globally and #853 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prescient Therapeutics Ltd's stock price AU$0.05 by its total outstanding shares 1051514543 (1.05 Billion). Analyse Prescient Therapeutics Ltd (PTX) cash flow conversion to see how efficiently the company converts income to cash.
Prescient Therapeutics Ltd Market Cap History: 2015 to 2026
Prescient Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $68.75 Million to $40.18 Million (-0.64% CAGR).
Prescient Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prescient Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.35x
Prescient Therapeutics Ltd's market cap is 14.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $63.17 Million | $10.70K | -$1.75 Million | 5901.23x | N/A |
| 2017 | $49.25 Million | $166.22K | -$2.57 Million | 296.32x | N/A |
| 2018 | $50.67 Million | $939.77K | -$2.57 Million | 53.91x | N/A |
| 2019 | $45.38 Million | $72.11K | -$3.80 Million | 629.38x | N/A |
| 2020 | $49.85 Million | $1.03 Million | -$3.32 Million | 48.44x | N/A |
| 2021 | $171.12 Million | $1.19 Million | -$4.15 Million | 144.41x | N/A |
| 2022 | $100.44 Million | $1.89 Million | -$5.12 Million | 53.17x | N/A |
| 2023 | $46.13 Million | $2.43 Million | -$7.00 Million | 19.00x | N/A |
| 2024 | $37.20 Million | $3.71 Million | -$8.24 Million | 10.02x | N/A |
| 2025 | $62.50 Million | $4.36 Million | -$7.32 Million | 14.35x | N/A |
Competitor Companies of PTX by Market Capitalization
Companies near Prescient Therapeutics Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Prescient Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Prescient Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Prescient Therapeutics Ltd's market cap moved from $68.75 Million to $ 40.18 Million, with a yearly change of -0.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$40.18 Million | -35.71% |
| 2025 | AU$62.50 Million | +68.00% |
| 2024 | AU$37.20 Million | -19.35% |
| 2023 | AU$46.13 Million | -54.07% |
| 2022 | AU$100.44 Million | -41.30% |
| 2021 | AU$171.12 Million | +243.28% |
| 2020 | AU$49.85 Million | +9.84% |
| 2019 | AU$45.38 Million | -10.43% |
| 2018 | AU$50.67 Million | +2.87% |
| 2017 | AU$49.25 Million | -22.03% |
| 2016 | AU$63.17 Million | -8.12% |
| 2015 | AU$68.75 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Prescient Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.18 Million USD |
| MoneyControl | $40.18 Million USD |
| MarketWatch | $40.18 Million USD |
| marketcap.company | $40.18 Million USD |
| Reuters | $40.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more